Shots:

• The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks.
• The therapy has shown similar efficacy and safety profile of CT-P13 IV and provides patients an opportunity of self-administration to control their own treatment
• The company applied patent protection until 2038 for Remsima SC in ~ 100 countries throughout North America- EU and Asia and will be the first product to enter the Canadian market

 ­ Ref: Newswire Canada | Image: Celltrion